Dementia Discovery Fund Healthcare News

This is selected healthcare news for Dementia Discovery Fund, which is filed under Capital Firms. There are 43 news items for this page. A press release filter page is also available for Dementia Discovery Fund.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/21/2022 Progress in Emerging Alzheimer's Therapeutics Based on Biology of Aging to be Highlighted in Session Moderated by Alzheimer's Drug Discovery Foundation (ADDF) at 2022 Clinical Trials on Alzheimer's Disease Conference
... related dementias, as well as a roundtable moderated by Niranjan Bose , Managing Director, Health & Life Sciences at Gates Ventures, featuring four global investment organizations ‚Ai Dementia Discovery Fund, Gates Ventures, EQT Life Sciences, and the ADDF ‚Ai to discuss the path forward for the Alzheimer's research field. CTAD will also ...
PR Newswire
5/31/2022 Transine Therapeutics Announces Final Closing of its Seed Round at £13.7m to Accelerate its Platform and Portfolio Development
... it has successfully raised ¬£4.6 million in additional seed funding. The financing was led by new investor Epidarex Capital with participation from existing investor the Dementia Discovery Fund (DDF). These new funds will enable Transine to further exploit its unique SINEUP¬AE platform and accelerate the development of its product ...
PR Newswire
6/2/2021 Transine Therapeutics Closes Extended Seed Funding of £9.1 million co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund to advance its novel class of therapeutic RNAs
... SINEUP¬AE platform technology, announces that it successfully secured ¬£9.1 million in seed funding. The financing was co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund (DDF), and will enable Transine to further develop its proprietary platform towards building a pipeline of novel mRNA-targeted therapeutics initially focused ...
FirstWord PHARMA
4/15/2021 Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics | Business Wire
... The international investment syndicate is led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by SV Health Investors who led the Seed round in 2019. The proceeds will be used to advance ...
Business Wire
4/15/2021 Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
... The international investment syndicate is led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by SV Health Investors who led the Seed round in 2019. The proceeds will be used to advance ...
Yahoo News
4/15/2021 The Ridgway Record
... The international investment syndicate is led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by SV Health Investors who led the Seed round in 2019. The proceeds will be used to advance ...
ridgwayrecord.com
4/15/2021 Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
... The international investment syndicate is led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by SV Health Investors who led the Seed round in 2019. The proceeds will be used to advance ...
Business Wire
7/21/2020 Cerevance Expands Series B Financing to $65 Million
... Capital added to its investment made in the first closing. Cerevance's previous closing also included GV (formerly Google Ventures), Bill Gates, Takeda Ventures, Inc., the Dementia Discovery Fund and Lightstone Ventures. “Cerevance uses its powerful NETSseq platform to uncover drivers of disease and aging in a unique tissue collection of ...
Globe Newswire
7/21/2020 $65m investment increases British Patient Capital’s exposure to life sciences and health technology
... medicine drugs for poorly treated diseases. The commitment increases British Patient Capital's exposure to life sciences and health technology, building on a commitment to the Dementia Discovery Fund in 2018. The IMF is SV's first dedicated biotech fund, with a mission to turn scientific breakthroughs into successful biotech companies producing ...
News Medical Net
7/21/2020 Cerevance Expands Series B Financing to $65 Million
... Capital added to its investment made in the first closing. Cerevance's previous closing also included GV (formerly Google Ventures), Bill Gates, Takeda Ventures, Inc., the Dementia Discovery Fund and Lightstone Ventures. "Cerevance uses its powerful NETSseq platform to uncover drivers of disease and aging in a unique tissue collection of ...
Benzinga
7/21/2020 Cerevance Expands Series B Financing to $65 MillionIncreases Funds to Develop Therapeutics Acting on Novel Targets for Brain Diseases
... Capital added to its investment made in the first closing. Cerevance's previous closing also included GV (formerly Google Ventures), Bill Gates, Takeda Ventures, Inc., the Dementia Discovery Fund and Lightstone Ventures. “Cerevance uses its powerful NETSseq platform to uncover drivers of disease and aging in a unique tissue collection of ...
BioSpace
7/21/2020 Cerevance Expands Series B Financing to $65 Million
... Capital added to its investment made in the first closing. Cerevance’s previous closing also included GV (formerly Google Ventures), Bill Gates, Takeda Ventures, Inc., the Dementia Discovery Fund and Lightstone Ventures. “Cerevance uses its powerful NETSseq platform to uncover drivers of disease and aging in a unique tissue collection of ...
vcaonline.com
6/2/2020 AstronauTx Announces an Alliance With Concept Life Sciences to Accelerate the Identification of Novel Therapies For Alzheimer's Disease
... expertise at AstronauTx to identify a novel candidate therapy for Alzheimer's disease. AstronauTx was formed in March 2019 with a £6.5 million investment from the Dementia Discovery Fund (DDF) and subsequently attracted a further £1 million from the UCL Technology Fund. The partnership with Concept Life Sciences is the second ...
PR Newswire
4/25/2020 Funding Roundup: Company creating ‘digital twins’ for clinical trials raises $12M
... for Parkinson's disease and other age-related conditions, closed a $38 million funding round led by Sofinnova Partners and AbbVie Ventures. Other investors include the Dementia Discovery Fund, Mission Bay Capital and Alexandria Venture Investmnets. As part of the investment, Sofinnova Managing Partner Henrijette Richter, AbbVie Managing Director Margarita Chavez ...
MedCity News
4/22/2020 Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases
... by Sofinnova Partners, a leading European life sciences venture capital firm, and AbbVie Ventures, AbbVie's corporate strategic venture capital arm, with further participation from the Dementia Discovery Fund, Mission Bay Capital and Alexandria Venture Investments. Henrijette Richter, Ph.D., Managing Partner of Sofinnova Partners, Margarita Chavez, Managing Director of AbbVie Ventures ...
Business Wire
4/22/2020 Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases
... by Sofinnova Partners, a leading European life sciences venture capital firm, and AbbVie Ventures, AbbVie's corporate strategic venture capital arm, with further participation from the Dementia Discovery Fund, Mission Bay Capital and Alexandria Venture Investments. Henrijette Richter, Ph.D., Managing Partner of Sofinnova Partners, Margarita Chavez, Managing Director of AbbVie Ventures ...
Business Wire
4/14/2020 Cerevance Closes $45 Million Series B Financing
... Capital, as well as all of the company's previous investors, which include Takeda Ventures, Inc., the corporate venture arm of Takeda Pharmaceutical Company, Ltd., the Dementia Discovery Fund and Lightstone Ventures. Cerevance will use the proceeds of the financing to continue identifying novel therapeutic targets for central nervous system diseases ...
Globe Newswire
1/8/2020 Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020 - Business Wire
... feature brief presentations from a panel of neuroscience drug development experts followed by a roundtable discussion moderated by co-chairs Christian Jung, Partner at the Dementia Discovery Fund, and Sumant Kulkarni, Managing Director of Biotechnology Equity Research at Canaccord Genuity LLC. About Cortexyme, Inc. Cortexyme (Nasdaq: CRTX) is a clinical ...
Business Wire
10/31/2019 Frustrated By Alzheimer’s BioPharma Research, Bill Gates Is Hesitant To ‘Throw More Money At Problem,’ Adviser Says
... has been far more restrained in bankrolling research into Alzheimer's disease. One of the first investments made by the billionaire's Gates Ventures was in the Dementia Discovery Fund, which invests in novel science. But, all told, Gates' Alzheimer's investments only total roughly $100 million, which even Gates' chief science adviser ...
Kaiser Health News
10/31/2019 STAT Plus: Bill Gates spends billions on global health. With Alzheimer’s, his science adviser says, money is not the issue
... has been far more restrained in bankrolling research into Alzheimer's disease. One of the first investments made by the billionaire's Gates Ventures was in the Dementia Discovery Fund, which invests in novel science. But, all told, Gates' Alzheimer's investments only total roughly $100 million, which even Gates' chief science adviser ...
STAT
10/31/2019 Why Bill Gates' spending on Alzheimer's research is modest
... has been far more restrained in bankrolling research into Alzheimer's disease. One of the first investments made by the billionaire's Gates Ventures was in the Dementia Discovery Fund, which invests in novel science. But, all told, Gates' Alzheimer's investments only total roughly $100 million, which even Gates' chief science adviser ...
STAT
10/22/2019 Bicycle Therapeutics Expands Neuroscience Collaborations to Include Oxford University’s Oxford Drug Discovery Institute
... Drug Discovery Institute (ODDI) to use Bicycle ® technology for the development of novel therapeutics for dementia. This expands upon the collaboration between Bicycle and the Dementia Discovery Fund, or DDF, a specialized venture capital fund focused on discovering and developing novel therapies for dementia, announced in May. “Our goal for ...
Business Wire
10/22/2019 Bicycle Therapeutics Expands Neuroscience Collaborations to Include Oxford University’s Oxford Drug Discovery Institute
... Drug Discovery Institute (ODDI) to use Bicycle ® technology for the development of novel therapeutics for dementia. This expands upon the collaboration between Bicycle and the Dementia Discovery Fund, or DDF, a specialized venture capital fund focused on discovering and developing novel therapies for dementia, announced in May. “Our goal for ...
Business Wire
10/18/2019 Associate / Analyst, Dementia Discovery Fund, SV Health Investors
Posted about 4 hours ago Expires on December 17, 2019 ASSOCIATE / ANALYST , DEMENTIA DISCOVERY FUND , SV HEALTH INVESTORS The Dementia Discovery Fund is looking for an ambitious and highly- motivated Associate / Analyst with a deep scientific understanding and a strong entrepreneurial spirit to join the investment team in Boston. This ...
Nature
9/27/2019 Ribometrix Announces $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform | Business & Finance | heraldchronicle.com
DURHAM, N.C.--(BUSINESS WIRE)--Sep 27, 2019-- Ribometrix , a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, today announced $7.8 million in additional funding from existing investors, the Dementia Discovery Fund and Illumina Ventures. Ribometrix also announced the appointment of Mike Clayman, M.D., as ...
Business Wire